Year-end Sale % OFF 
Abstract
Sodium-glucose cotransporter-2 inhibitors (SGLT2I) have been reported to have renal-protective effects in patients with type 2 diabetes (T2DM). This a retrospective study aimed to evaluate the effect of SGLT2I on renal function in patients with nonalcoholic fatty liver disease (NAFLD) and T2DM. We analyzed 69 consecutive patients with a biopsy-proven NAFLD and T2DM with an estimated glomerular filtration rate (eGFR) >60 mL/min. Of these 69 patients, 22 received SGLT2I and 47 were treated without SGLT2I. Liver function and eGFR were analyzed at baseline and after three years. Body mass index, liver function and HbA1c improved significantly in both groups. In the total population, the median eGFR declined from 80.7 mL/min at the baseline to 74.9 mL/min at the end of follow-up. The median eGFR at the baseline/end of follow-up was 81.2/80.4 mL/min in patients treated with SGLT2I and 80.2/70.8 mL/min in patients treated without SGLT2I. Multivariate analysis identified an increased FIB-4 index with an odds ratio (OR) of 4.721, (p = 0.045) and SGLT2I treatment (OR 0.263, p = 0.033) as predictive factors for decreased eGFR. SGLT2I treatment has a protective effect on the renal function for NAFLD with T2DM. A long-term, randomized, controlled trial is warranted to confirm the renal protective effect of SGLT2I in NAFLD patients with T2DM.
Highlights
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Japan, and it affects up to 25–30% of the general adult population worldwide [1]
This study aims to clarify the association between liver function and renal function in the follow-up period and the impact of Sodium-glucose cotransporter-2 inhibitors (SGLT2I) treatment on renal function in nonalcoholic fatty liver disease (NAFLD) patients with type 2 diabetes mellitus (T2DM)
We investigated the effect of SGLT2I on renal function in patients with
Summary
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in Japan, and it affects up to 25–30% of the general adult population worldwide [1]. NAFLD is known to be associated with extrahepatic diseases, such as type 2 diabetes mellitus (T2DM), cardiovascular (CV) disease and chronic kidney disease (CKD) [2,3,4]. The association between NAFLD and CKD has attracted considerable attention, and many studies support the concept that NAFLD affects the incidence of CKD [5,6]. Patients with NAFLD have a high risk of incident CKD, which is considered to be associated with the severity of the NAFLD. Among patients with NAFLD, the presence of T2DM increases the risk of the development of CKD [7,8]. There are no established pharmacotherapies for NAFLD in patients with
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
